2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC
  5. Drug-Linker Conjugates for ADC Isoform

Drug-Linker Conjugates for ADC

 

Drug-Linker Conjugates for ADC Related Products (186):

Cat. No. Product Name Effect Purity
  • HY-145951
    Amidate-VC-PAB-MMAF
    Amidate-VC-PAB-MMAF consists a cleavable ADC linker (Amidate-VC-PAB) and a potent tubulin polymerization inhibitor (MMAF). Amidate-VC-PAB-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs). Amidate-VC-PAB-MMAF reduces off-target cytotoxicity of ADCs.
  • HY-153907
    SMP-88480
    SMP-88480 is an Antibody-Drug Conjugates (ADCs). SMP-88480 is stable in mouse, monkey and human plasma and has in vivo tumor inhibitory effects on ovarian cancer, gastric cancer, and breast cancer.
  • HY-170865
    OncoFAP-GlyPro-MMAF
    OncoFAP-GlyPro-MMAF is a Drug-Linker Conjugate for ADC with potent antitumor activity. OncoFAP-GlyPro-MMAF consists of Monomethylauristatin F (HY-15579) and a linker. OncoFAP-GlyPro-MMAF can be used for synthesis of ADCs.
  • HY-156691
    TLR7/8 agonist 4 hydroxy-PEG6-acid
    TLR7/8 agonist 4 hydroxy-PEG6-acid is a drug-linker conjugates for ADC. TLR7/8 agonist 4 hydroxy-PEG6-acid consists of TLR7/8 agonist 4 (HY-139017) and a non-cleavable linker Hydroxy-PEG6-acid (HY-133050), and can be used for synthesis of ADCs.
  • HY-145078
    PNU-EDA-Gly5
    PNU-EDA-Gly5 is an oligo-glycine linker-payload for ADC synthesis, composed of a DNA topoisomerase I inhibitor PNU-159682 and a linker EDA-Gly5.
  • HY-169324
    APL-1092
    APL-1092 (Mal-Exo-EEVC-Exatecan) is a drug-linker conjugate for ADC, which contains Exatecan (HY-13631) (ADC payload) and a linker.
  • HY-152916
    mp-dLAE-PABC-MMAE
    mp-dLAE-PABC-MMAE is a agent-linker conjugate for ADC. mp-dLAE-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (HY-15162). mp-dLAE-PABC-MMAE can be used to synthesis antibody-drug conjugates (ADCs).
  • HY-164837
    VcMMAE-Eribulin
    VcMMAE-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule MMAE (HY-15162) (Microtubule inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). VcMMAE-Eribulin can be used for ADC synthesis.
  • HY-164303
    Val-Cit-PAB-DEA-Duo-DM
    Val-Cit-PAB-DEA-Duo-DM is a drug-linker conjugate, which consists of the linker Val-Cit-PAB, the spacer DEA and the ADC toxin Duocarmycin DM (Duo-DM) (HY-130978). Val-Cit-PAB-DEA-Duo-DM can be used for the synthesis of ADC molecule.
  • HY-148459
    ATAC21
    ATAC21, a linker-immune-stimulatory compound that can be formed by conjugating a noncleavable maleimide-PEG4 linker containing a succinimide group with an immune- stimulatory compound. ATAC21 can be combined with SBT-040 (anti-CD40 antibody) to form a conjugate.
  • HY-171138
    Mal-VC-PAB-DMEA-PNU-159682
    Mal-VC-PAB-DMEA-PNU-159682 is a agent-linker conjugate for ADC with potent antitumor activity by using the anti-topoisomerase II agent, PNU-159682, linked via the lysosomally cleavable dipeptide, Mc-VC-PAB. Mal-VC-PAB-DMEA-PNU-159682 can be used in the synthesis of Anti-CD22-NMS249 (HY-164761).
  • HY-128979B
    Deruxtecan analog 2 monoTFA
    		99.56%
    Deruxtecan analog 2 (monoTFA) is a homolog of Deruxtecan (HY-13631E), a conjugate of the ADC toxin DX-8951 derivative (Dxd) with an ADC Linker.
  • HY-147231
    SG3400 delate(Mal-amido-PEG8)
    SG3400 delate (Mal-amido-PEG8) (compound 21) is an intermediate for the synthesis of ADC molecules. SG3400 delete is an effective toxin molecule with anticancer activity. SG3400 delete can be used in cancer research.
  • HY-156514
    MC-GGFG-AM-(10NH2-11F-Camptothecin)
    MC-GGFG-AM-(10NH2-11F-Camptothecin) is an antibody drug conjugates (ADC). MC-GGFG-AM-(10NH2-11F-Camptothecin) binds to the anti-TROp-2 antibody sacituzumab via a hydrolysable pH-sensitive linker and has anti-tumor activity. MC-GGFG-AM-(10NH2-11F-Camptothecin) can be used for cancer research.
  • HY-168317
    LNK2-S
    LNK2-S is a conjugated compound of toxin molecule Exatecan (HY-13631) and Linker, which can be used to synthesize ADC molecule.
  • HY-156897
    Val-Cit-amide-Ph-Maytansine
    		98.01%
    Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocyte growth factor receptor c-Met (MET) or antibody-drug conjugates (ADCs).
  • HY-160180
    Glucocorticoid receptor agonist-4 Ala-Ala-Mal
    Glucocorticoid receptor agonist-4 Ala-Ala-Mal (Compound Preparation 9) is an anti-human TNFα antibody-glucocorticoid receptor agonist (GC) conjugate. Glucocorticoid receptor agonist-4 Ala-Ala-Mal can be used in the study of autoimmune and inflammatory diseases.
  • HY-161780
    Maleimide-PEG8-Val-Ala-PAB-SNS032
    Maleimide-Val-Ala-PAB-SNS032 is a conjugate of ADC toxin and linker. SNS032 is an inhibitor for CDK, inhibiting the cell cycle at G1/S phase and cell viability of cancer cells. Maleimide-Val-Ala-PAB is a cleavable ADC linker. Maleimide-Val-Ala-PAB-SNS032 can be utilized for the synthesis of ADC molecules.
  • HY-170868
    CL2A-FL118
    CL2A-FL118 is a drug-linker for synthesis of ADC molecule Sac-CL2A-FL118.
  • HY-164656
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE
    DOTA-tris(acid)-amido-PEG24-amido-PEG24-DSPE is a radionuclide conjugate (RDC), which is capable of binding to a radionuclide. RDC has the ability to specifically target biomolecules and can be used in medical imaging or therapy.